secwatch.observer — SEC 8-K summary
======================================

Issuer:     BICYCLE THERAPEUTICS PLC (BCYC)
CIK:        0001761612
Form:       8-K
Filed at:   2022-11-03T23:59:59+00:00
Accession:  0001104659-22-114205
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bicycle Therapeutics reports Q3 net loss $28.3M; cash $361.5M; clinical pipeline progressing
--------------------------------------------------------------------------------

- Net loss of $28.3M ($0.96 per share) vs $14.7M ($0.59) in Q3 2021.
- Cash and equivalents $361.5M at Sep 30, 2022 ($438.7M Dec 31, 2021); runway into 2025.
- R&D expenses $22.8M (up from $10.5M) driven by BT5528, BT8009, and platform costs.
- Received $10M option fee from Genentech for expansion of immuno-oncology collaboration.
- BT5528 showed 22% ORR in ovarian, 67% in urothelial; expansion enrollment on track for Q4 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1761612/000110465922114205/0001104659-22-114205-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1761612/000110465922114205/tm2229573d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-114205

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer